Clinical Trial

Safety and Immunogenicity of the Recombinant Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 18 Years and Older

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This phase 1 study in China will evaluate the safety and immunogenicity of the the Respiratory Syncytial Virus (RSV) Vaccine, LYB005 in adults aged 18 years and older.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-31.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-08-18
Trial Details
NCT Number NCT06904222
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Conditions Respiratory Syncytial Virus Infection
Enrollment 90 participants
Start Date 2025-04-15
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-22